Home › Acute Myeloid Leukemia › Georgia
Acute Myeloid Leukemia clinical trials in Georgia
38 studies for Acute Myeloid Leukemia are looking for participants at sites in Georgia.
Cities in Georgia
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
- Winship Cancer Institute of Emory University /ID# 279006, Atlanta
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07581002Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Northeast Georgia Medical Center Braselton, Braselton
- Atlanta VA Medical Center, Decatur
- Northeast Georgia Medical Center-Gainesville, Gainesville
- and 4 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Emory University Hospital/Winship Cancer Institute, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06484062Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Healthcare of Atlanta - Arthur M. Blank Hospital, Atlanta
RecruitingObservational study
Ages 0 to 38 · All sexes · Updated Oct 1, 2026 · NCT06131801A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- Emory University, Atlanta
RecruitingPhase 1
Ages 12 to 78 · All sexes · Updated Sep 29, 2026 · NCT03802695Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Phoebe Putney Memorial Hospital, Albany
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Sep 28, 2026 · NCT05554393MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Phoebe Putney Memorial Hospital, Albany
- Augusta University Medical Center, Augusta
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05564390A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
RecruitingPhase 1
Up to age 21 · All sexes · Updated Sep 23, 2026 · NCT07012044Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Phoebe Putney Memorial Hospital, Albany
- Augusta University Medical Center, Augusta
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Augusta University Medical Center, Augusta
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Phoebe Putney Memorial Hospital, Albany
- Augusta University Medical Center, Augusta
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Sep 22, 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
- Augusta University Medical Center, Augusta
- Memorial Health University Medical Center, Savannah
RecruitingPhase 3
6 Months – 21 Years · All sexes · Updated Sep 17, 2026 · NCT04293562A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Emory Winship Cancer Institute, Atlanta
RecruitingPhase 1/2
30 Days · All sexes · Updated Sep 16, 2026 · NCT04065399(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Winship Cancer Institute - Emory University, Atlanta
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT04996875Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
RecruitingPhase 3
Ages 1 to 25 · All sexes · Updated Sep 4, 2026 · NCT07022678Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- City of Hope - Atlanta, Newnan
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 3, 2026 · NCT04588922Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Atlanta GA-EMORY, Atlanta
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06652438Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
- US-Atlanta GA-EMORY, Atlanta
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 1, 2026 · NCT07223814The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
- Memorial Health University Medical Center, Savannah
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Children's Healthcare of Atlanta, Atlanta
RecruitingPhase 3
29 Days – 21 Years · All sexes · Updated Aug 24, 2026 · NCT05183035Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Emory Healthcare - The Emory Clinic, Atlanta
- Georgia Cancer Center at Augusta University, Augusta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT06001788L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
- Augusta University - Georgia Cancer Center, Augusta
RecruitingPhase 2/3
Ages 18 to 80 · All sexes · Updated Aug 5, 2026 · NCT06788756Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Children's Healthcare of Atlanta, Atlanta
RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Aug 3, 2026 · NCT06177067A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- Northside Hospital, Atlanta
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 75 · All sexes · Updated Jul 28, 2026 · NCT07020533Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- Emory University - Winship Cancer Institute (WCI), Atlanta
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Jul 17, 2026 · NCT05429632A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Children's Healthcare of Atlanta, Atlanta
- Northside Hospital, Atlanta
- Georgia Cancer Center at Augusta University Health, Augusta
RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- Emory Winship Cancer Institute, Atlanta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 24, 2026 · NCT04068597Ivosidenib as Post-HSCT Maintenance for AML
- Emory University Hospital, Atlanta
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Jun 18, 2026 · NCT06707493BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
- Winship Cancer Institute / Emory University, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 15, 2026 · NCT05768932A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- University of Emory - Winship Cancer Institute, Atlanta
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT04256317Pilot Imaging Study of Leukemia
- Emory University, Atlanta
RecruitingPhase 1
Ages 4 to 80 · All sexes · Updated Apr 23, 2026 · NCT03633955A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Emory Healthcare - The Emory Clinic, Atlanta
- Georgia Cancer Center at Augusta University, Augusta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT05735184CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- Northside Hospital, Atlanta
RecruitingPhase 2Healthy volunteers welcome
Ages 18 to 75 · All sexes · Updated Mar 10, 2026 · NCT06059391CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Emory University Hospital, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jan 16, 2026 · NCT05143996Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
- Emory University - WINSHIP Cancer Center, Atlanta
- Emory University, Children's Healthcare of Atlanta, Atlanta
RecruitingPhase 1
Ages 12 and older · All sexes · Updated Jan 8, 2026 · NCT04872478Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Blood and Marrow Transplant Group of Georgia, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 31, 2025 · NCT06549790Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- Emory University, Atlanta
RecruitingHealthy volunteers welcome
Ages 18 to 120 · All sexes · Updated Jul 25, 2025 · NCT05237258Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- Georgia Cancer Center at Augusta University, Augusta
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 7, 2025 · NCT02781883From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.